sign in sign up
<<
Home , Alectinib, Cancer immunotherapy, Entrectinib, Sorafenib, Trastuzumab emtansine

Media Release

New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in care  First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer , in combination with Tecentriq® () in patients with PD-L1-positive metastatic non- small cell (NSCLC)  Updated overall survival data for Alecensa® (), in people living with anaplastic (ALK)-positive metastatic NSCLC  Key highlights to be shared on Roche’s ASCO virtual newsroom, 29 May 2020, 08:00 CEST

Basel, 7 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 21 cancer types, will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical (ASCO), which will be held 29-31 May, 2020. A total of 120 abstracts that include a Roche medicine will be presented at this year's meeting.

"At ASCO, we will present new data from many investigational and approved medicines across our broad oncology portfolio," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “These efforts exemplify our long-standing commitment to improving outcomes for people with cancer, even during these unprecedented times. By integrating our medicines and diagnostics together with advanced insights and novel platforms, Roche is uniquely positioned to deliver the healthcare solutions of the future."

Together with its partners, Roche is pioneering a comprehensive approach to cancer care, combining new diagnostics and treatments with innovative, integrated data and access solutions for approved medicines that will both personalise and transform the outcomes of people affected by this deadly disease.

Key presentations First results of tiragolumab, Roche’s novel designed to bind to TIGIT, will be shared. These results, from the phase II CITYSCAPE study, examine tiragolumab in combination with Tecentriq® (atezolizumab) compared with Tecentriq alone as an initial treatment for people with PD-L1-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC). In addition, updated five-year overall survival rates with Alecensa® (alectinib) in people living with treatment-naive anaplastic lymphoma kinase (ALK)-positive metastatic/advanced NSCLC will be presented. With five approved lung cancer medicines and an extensive pipeline across multiple subtypes, Roche's ultimate aim is to provide an effective treatment option for each person diagnosed with the disease, tailored to the unique characteristics of their tumours.

Studies featured from partnerships with Flatiron Health and Foundation Medicine demonstrate how the use of next-generation sequencing (NGS) may help inform treatment decisions, optimise testing and enable

F. Hoffmann-La Roche Ltd 4070 Basel Group Communications Tel. +41 61 688 88 88 Switzerland Roche Group Media Relations www.roche.com

1/6

personalised , including an ongoing additional study designed to prospectively link longitudinal, real- world clinical data with genomic, imaging and outcomes data for patients with advanced lung . The study is monitoring circulating tumour DNA (ctDNA) using FoundationOne® Liquid, and tumour tissue samples will be genomically profiled using FoundationOne® CDx.

Based on this year’s virtual format, Roche will be launching a virtual newsroom for journalists to access further information on our contribution to the ASCO20 Virtual Scientific Program, as well as the latest innovations and developments in Roche’s approach to accelerating progress in cancer care. The newsroom will be available on Friday 29 May, 08:00 CEST, and open to journalists from outside the United States.

To access Roche’s ASCO virtual newsroom, please register via this link: https://asco2020media.roche.com

Follow Roche on Twitter via @Roche and keep up to date with ASCO news and updates by using the hashtag #ASCO20.

Overview of key presentations featuring Roche medicines at ASCO 2020

Medicine Abstract title Abstract number

Lung cancer

Tiragolumab Primary analysis of a randomized, double-blind, phase II #9503 study of the anti-TIGIT tiragolumab (tira) plus Oral abstract session atezolizumab (atezo) versus placebo plus atezo as first- line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)

Alecensa Updated overall survival (OS) and safety data from the #9518 (alectinib) randomized, phase III ALEX study of alectinib (ALC) Poster: 284 versus (CRZ) in untreated advanced ALK+ Poster discussion NSCLC session

Tecentriq Patient-reported outcomes (PROs) in the randomized, #9594 (atezolizuma phase III IMpower110 study of atezolizumab (atezo) vs Poster: 360 b) in 1L metastatic NSCLC Poster session

Tecentriq IMpower150: exploratory analysis of brain metastases #9587 development Poster: 353 Poster session

Tecentriq IMpower150: exploratory efficacy analysis in patients N/A (pts) with bulky disease e-publication

2/6

Flatiron Health data in lung cancer

Real World A multi-stakeholder platform to prospectively link #TPS2087 Data longitudinal real-world clinico-genomic, imaging, and Poster: 79 outcomes data for patients with metastatic lung cancer Poster session

Real World Genomic testing among patients (pts) with newly #9592 Data diagnosed advanced non-small cell lung cancer Poster: 358 (aNSCLC) in the United States: a contemporary clinical Poster session practice patterns study

Solid tumours

Rozlytrek Updated data in children and adolescents #107 (entrectinib) with recurrent or refractory solid tumors, including Clinical primary CNS tumor symposium

Rozlytrek Efficacy and safety of entrectinib in patients (pts) with #3605 NTRK-Fusion-Positive (NTRK-fp) solid tumors: An Poster: 335 updated integrated analysis Poster session

Genitourinary and gastrointestinal cancers

Tecentriq IMvigor010: primary analysis from a phase III #5000 randomized study of adjuvant atezolizumab (atezo) Oral abstract session versus observation (obs) in high-risk muscle-invasive urothelial (MIUC)

Tecentriq Tumor, immune, and stromal characteristics associated #5011 with clinical outcomes with atezolizumab (atezo) + Clinical science platinum-based chemotherapy (PBC) or atezo symposium monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study

Tecentriq Phase Ib/II open-label, randomized evaluation of 2L #4540 atezolizumab + PEGPH20 versus control in Poster: 148 MORPHEUS-pancreatic ductal adenocarcinoma (M- Poster session PDAC) and MORPHEUS-gastric cancer (M-GC)

Tecentriq, Complete responses (CR) in patients receiving #4596 Avastin atezolizumab (atezo) + (bev) vs Poster: 204 (bevacizuma (sor) in IMbrave150: a phase III for Poster session b) unresectable (HCC)

3/6

Ipatasertib Circulating tumor DNA (ctDNA) dynamics associate #5508 with treatment response and radiological progression- Oral abstract session free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant (mCRPC)

Blood cancer

Venclexta Impact of premature (Ven) #8028 (venetoclax) discontinuation/interruption on outcomes in Poster: 361 relapsed/refractory (R/R) chronic lymphocytic Poster session (CLL): Phase III MURANO study results

Venclexta, Fixed-duration venetoclax- for previously #8027 Gazyva untreated patients with chronic lymphocytic leukemia: Poster: 360 (obinutuzum follow-up of efficacy and safety results from the Poster session ab) multicenter, open-label, randomized, phase III CLL14 trial

Gazyva Comparison of efficacy and safety with obinutuzumab #8023 plus chemotherapy versus plus chemotherapy Poster: 356 in patients with previously untreated follicular Poster session lymphoma – Updated results from the phase III Gallium Study

Breast cancer

Kadcyla Primary analysis of KAITLIN: A phase III study of #500 (trastuzuma emtansine (T-DM1) + versus Oral abstract session b trastuzumab + pertuzumab + , after emtansine), as for high-risk HER2-positive early Perjeta (EBC) (pertuzumab )

Kadcyla Biomarker data from KATHERINE: A phase III study of #502 adjuvant (T-DM1) versus Oral abstract session trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer

About Roche in Oncology Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, , to patients in 1962. Roche’s commitment to

4/6

developing innovative medicines and diagnostics for cancers remains steadfast.

The Roche Group’s portfolio of innovative cancer medicines includes: Alecensa® (alectinib); Avastin® (bevacizumab); Cotellic® (); Erivedge® (); Gazyva®/Gazyvaro® (obinutuzumab); Herceptin® (trastuzumab); Kadcyla® (trastuzumab emtansine); MabThera®/Rituxan® (rituximab); Perjeta® (pertuzumab); Polivy® (-piiq); Tarceva® (); RozlytrekTM (entrectinib); Tecentriq® (atezolizumab); Venclexta®/Venclyxto® (venetoclax); Xeloda® (); Zelboraf® (). Furthermore, the Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies. For more information on Roche’s approach to cancer, visit www.roche.com.

About Roche in Personalised Healthcare For more than 20 years, Roche has helped lay the scientific groundwork for personalised healthcare with treatments that target the underlying biology of cancer and other diseases. Now, with profound changes in data and technology transforming how medicines are discovered, developed and delivered to patients, we are uniquely positioned to extend this approach across all of healthcare. With our ability to integrate research and development, personalised diagnosis, disease monitoring and treatment access, we are advancing personalised healthcare for every aspect of the patient experience.

Our strategy is rooted in groundbreaking science that can accelerate drug discovery and development. We are also leveraging technologies such as real-world datasets, artificial intelligence, genomic profiling and digital health across our therapeutic portfolio, with an initial emphasis on oncology, neurology, ophthalmology and diagnostics. Through collaborations with academic institutions, industry partners, patients, physicians and regulatory agencies, our goal is to dramatically improve the performance of the entire healthcare ecosystem and the lives of every patient.

About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

5/6

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. , in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: [email protected] - Nicolas Dunant (Head) - Patrick Barth - Daniel Grotzky - Karsten Kleine - Nathalie Meetz - Barbara von Schnurbein

6/6